Biologics and Biosimilars Market Will Gauged at 4.5% CAGR to Reach 297100 Million US$ by the End of 2025: QY Research, Inc.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
View full press release